• Polus, Development Director
  • MIT, Postdoc
  • University of Utah, Biochemistry, Ph.D

Sunghwan Kim, PhD / Biochemistry

Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies.

I am responsible for whether medicines actually works as a known biological effect, which is often called drug evaluation and mechanism research.

I studied microbiology in my undergraduate and acquired master’s degree in the peptide drug synthesis and protein structure. For my doctoral study, I studied the mechanism by which the HIV virus penetrates the cell and discovered a target site for an HIV virus invasion inhibitor. In addition, we proceeded with the development of therapeutics.

After completing my Ph.D., I continued research in the synthesis, folding, and transport of proteins in Dr. Kaiser’s laboratory, where he served as Vice President of the Department of Biology at MIT. During my post-doctoral study, I have discovered enzymes that are important for protein synthesis and folding, and revealed their biochemical and cellular biological mechanisms.

Later, at UCSF’s Cardiovascular Research Institute, I studied the biochemical mechanisms of receptor proteins that regulate vasodilation and contraction.

After years in academia, I started the full-fledged drug development research with the development of protein-based drug candidates, expression systems and purification, and formulation development in Korea. In addition, at the Drug Development Research Center, I have participated in the development of inhibitors for various target proteins by establishing an efficacy evaluation system for synthetic drug candidates, binding analysis with target proteins, and complex structure analysis.

Since then, I have led the mechanism research data, efficacy assessments, and biophysical chemical characterization at a biosimilar development company. I have established and managed an evaluation system that meets the pharmaceutical standards set forth by FDA and EMA. In the process, the USP, which is in charge of the US Pharmacopoeia, conducted verification of the new activity evaluation method for insulin drugs. As a result, we were invited to speak at the USP workshop in India this February and presented the results.

Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies. We are forming excellent doctoral / master-level researchers and building a research system optimized for new drug development projects. We develop our methods in accordance with the ICH guidelines and obtain reliable potency levels as in global standards.

In the case of new mechanism research, we are improving the degree of perfection through cooperation with all internal researchers, external advisors, and global research institutes.

  • Polus, Development Director
  • MIT, Postdoc
  • University of Utah, Biochemistry, Ph.D

Sunghwan Kim, PhD / Biochemistry

Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies.

I am responsible for whether medicines actually works as a known biological effect, which is often called drug evaluation and mechanism research.

I studied microbiology in my undergraduate and acquired master’s degree in the peptide drug synthesis and protein structure. For my doctoral study, I studied the mechanism by which the HIV virus penetrates the cell and discovered a target site for an HIV virus invasion inhibitor. In addition, we proceeded with the development of therapeutics.

After completing my Ph.D., I continued research in the synthesis, folding, and transport of proteins in Dr. Kaiser’s laboratory, where he served as Vice President of the Department of Biology at MIT. During my post-doctoral study, I have discovered enzymes that are important for protein synthesis and folding, and revealed their biochemical and cellular biological mechanisms.

Later, at UCSF’s Cardiovascular Research Institute, I studied the biochemical mechanisms of receptor proteins that regulate vasodilation and contraction.

After years in academia, I started the full-fledged drug development research with the development of protein-based drug candidates, expression systems and purification, and formulation development in Korea. In addition, at the Drug Development Research Center, I have participated in the development of inhibitors for various target proteins by establishing an efficacy evaluation system for synthetic drug candidates, binding analysis with target proteins, and complex structure analysis.

Since then, I have led the mechanism research data, efficacy assessments, and biophysical chemical characterization at a biosimilar development company. I have established and managed an evaluation system that meets the pharmaceutical standards set forth by FDA and EMA. In the process, the USP, which is in charge of the US Pharmacopoeia, conducted verification of the new activity evaluation method for insulin drugs. As a result, we were invited to speak at the USP workshop in India this February and presented the results.

Voronoi is aiming to secure research capacity and technology comparable to global pharmaceutical companies. We are forming excellent doctoral / master-level researchers and building a research system optimized for new drug development projects. We develop our methods in accordance with the ICH guidelines and obtain reliable potency levels as in global standards.

In the case of new mechanism research, we are improving the degree of perfection through cooperation with all internal researchers, external advisors, and global research institutes.